WPI 2245 (Mesalamine Delayed-Release 1.2 g)

Pill with imprint WPI 2245 is Brown, Elliptical / Oval and has been identified as Mesalamine Delayed-Release 1.2 g. It is supplied by Actavis Pharma, Inc..

Mesalamine is used in the treatment of crohn's disease, maintenance; inflammatory bowel disease; ulcerative colitis, maintenance; ulcerative colitis; ulcerative proctitis and belongs to the drug class 5-aminosalicylates. Excluding Asacol and Asacol HD: There is no proven risk in humans during pregnancy. Asacol and Asacol HD: Risk cannot be ruled out during pregnancy. Mesalamine 1.2 g is not a controlled substance under the Controlled Substances Act (CSA).

Images for WPI 2245

Save up to 80% off prescription medications

Click here for your free Discount Card

Mesalamine Delayed-Release

Imprint

WPI 2245

Strength

1.2 g

Color

Brown

Size

21.00 mm

Shape

Elliptical / Oval

Availability

Prescription only

Drug Class

5-aminosalicylates

Pregnancy Category

B - No proven risk in humans - excluding Asacol and Asacol HD, C - Risk cannot be ruled out - Asacol and Asacol HD

CSA Schedule

Not a controlled drug

Labeler / Supplier

Actavis Pharma, Inc.

National Drug Code (NDC)

00591-2245

Inactive Ingredients

copovidone, silicon dioxide, hypromellose 2910 (6 mPa.s), magnesium stearate, methacrylic acid - methyl methacrylate copolymer (1:1), methacrylic acid - methyl methacrylate copolymer (1:2), ferrosoferric oxide, ferric oxide red, ferric oxide yellow, microcrystalline cellulose, povidone k90, polyethylene glycol 400, polyethylene glycol 3350, polyethylene glycol 8000, propylene glycol, sodium starch glycolate type A potato, magnesium silicate, titanium dioxide, triethyl citrate

Note: Inactive ingredients may vary.

More Info Imprint Search Print

Get help with Imprint Code FAQs.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer